Why write ten lines of code when one will do? From magic variable swaps to high-speed data counting, these Python snippets ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

remove-circle Internet Archive's in-browser video "theater" requires JavaScript to be enabled. It appears your browser does not have it turned on. Please see your ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) SALT LAKE CITY, Aug. 05, 2025 ...